Back to top

Jazz Pharmaceuticals price target raised to $300 from $290 at Canaccord

Canaccord analyst Gary Nachman raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $300 from $290 and keeps a Buy rating on the shares...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Jazz Pharmaceuticals PLC (JAZZ)